IV期非小细胞肺癌的系统治疗:美国临床肿瘤学会临床实践指南更新
本指南更新基于2014年2月至2016年12月的随机对照试验系统综述,提供IV期非小细胞肺癌系统治疗的循证推荐。更新涉及一线PD-L1高表达用帕博利珠单抗单药、低表达用标准化疗,以及二线免疫检查点抑制剂和EGFR/ROS1突变患者的靶向治疗选择。
要点
- 一线非鳞或鳞癌无EGFR/ALK/ROS1阳性时,PD-L1高表达用帕博利珠单抗单药,低表达用标准化疗。
- 一线化疗后二线无既往免疫治疗,PD-L1阳性可用纳武利尤单抗、帕博利珠单抗或阿替利珠单抗单药。
- EGFR敏感突变一线EGFR-TKI进展后T790M阳性推荐奥希替尼,阴性推荐化疗。
核心结论
- 指南更新反映了自2015年更新以来的证据变化,对IV期非小细胞肺癌的一线和二线系统治疗提出新或修订推荐。
研究设计与样本
- 美国临床肿瘤学会(ASCO)非小细胞肺癌专家小组基于2014年2月至2016年12月随机对照试验的系统综述制定推荐,并参考Cancer Care Ontario循证护理项目对既往ASCO检索的更新。
- 证据基础包括14项随机对照试验,早期阶段试验也为推荐制定提供信息。
主要发现
- 一线治疗非鳞或鳞癌无阳性标志物(如EGFR/ALK/ROS1)时,PD-L1高表达患者应单用帕博利珠单抗,PD-L1低表达患者临床医生应提供标准化疗。
- 一线化疗后二线治疗且无既往免疫检查点治疗,PD-L1阳性非小细胞肺癌临床医生应使用纳武利尤单抗、帕博利珠单抗或阿替利珠单抗单药;PD-L1阴性或未知时临床医生应使用纳武利尤单抗或阿替利珠单抗。
- 所有免疫检查点治疗推荐单药使用,且无禁忌证。
- 既往一线免疫检查点抑制剂治疗的患者,临床医生应提供标准化疗。
- 化疗后不能接受免疫检查点抑制剂的患者推荐多西他赛;非鳞非小细胞肺癌患者推荐培美曲塞。
关键数值与推荐
- 一线非鳞或鳞癌无阳性标志物,PD-L1高表达:帕博利珠单抗单药;PD-L1低表达:标准化疗。
- 二线无既往免疫治疗,PD-L1阳性:纳武利尤单抗、帕博利珠单抗或阿替利珠单抗单药;PD-L1阴性或未知:纳武利尤单抗或阿替利珠单抗。
- 一线免疫检查点抑制剂后进展:标准化疗。
- 化疗后不能接受免疫检查点抑制剂:多西他赛;非鳞癌:培美曲塞。
- EGFR敏感突变T790M阳性:奥希替尼;T790M阴性:化疗。
临床怎么用
- 临床医生应根据PD-L1表达水平、EGFR/ALK/ROS1状态及既往治疗史选择一线和二线系统治疗方案。
- 免疫检查点抑制剂推荐单药使用,且需无禁忌证。
- 靶向治疗需基于相应分子标志物检测结果选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC). Methods The ASCO NSCLC Expert Panel made recommendations based on a systematic review of randomized controlled trials from February 2014 to December 2016 plus the Cancer Care Ontario Program in Evidence-Based Care's update of a previous ASCO search. Results This guideline update reflects changes in evidence since the previous guideline update. Fourteen randomized controlled trials provide the evidence base; earlier phase trials also informed recommendation development. Recommendations New or revised recommendations include the following. Regarding first-line treatment for patients with non-squamous cell carcinoma or squamous cell carcinoma (without positive markers, eg, EGFR/ALK /ROS1), if the patient has high programmed death ligand 1 (PD-L1) expression, pembrolizumab should be used alone; if the patient has low PD-L1 expression, clinicians should offer standard chemotherapy. All other clinical scenarios follow 2015 recommendations. Regarding second-line treatment in patients who received first-line chemotherapy, without prior immune checkpoint therapy, if NSCLC tumor is positive for PD-L1 expression, clinicians should use single-agent nivolumab, pembrolizumab, or atezolizumab; if tumor has negative or unknown PD-L1 expression, clinicians should use nivolumab or atezolizumab. All immune checkpoint therapy is recommended alone plus in the absence of contraindications. For patients who received a prior first-line immune checkpoint inhibitor, clinicians should offer standard chemotherapy. For patients who cannot receive immune checkpoint inhibitor after chemotherapy, docetaxel is recommended; in patients with nonsquamous NSCLC, pemetrexed is recommended. In patients with a sensitizing EGFR mutation, disease progression after first-line epidermal growth factor receptor tyrosine kinase inhibitor therapy, and T790M mutation, osimertinib is recommended; if NSCLC lacks the T790M mutation, then chemotherapy is recommended. Patients with ROS1 gene rearrangement without prior crizotinib may be offered crizotinib, or if they previously received crizotinib, they may be offered chemotherapy.
引用
- Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017. PMID: 28806116. doi:10.1200/JCO.2017.74.6065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。